GSK to Acquire U.S. Cancer Drugmaker Nuvalent for $10.6 Billion GlaxoSmithKline (GSK), the U.K. pharmaceutical giant, has agreed to acquire U.S.-based oncology biotech Nuvalent for $10.6 billion in an all-cash deal. The transaction, which values Nuvalent at approximately $124 per share—a 40% premium to its last closing price—marks GSK’s largest acquisition in over a decade. The deal is expected to bolster GSK’s oncology pipeline and address declining revenue from its HIV medication, which will lose exclusivity in 2028. Nuvalent’s shares surged 39% in premarket trading, while GSK’s stock dipped 2.6% in London following the announcement. The acquisition includes Nuvalent’s two late-stage lung cancer treatments, which GSK described as having “blockbuster potential.” These therapies, zidesamtinib and neladalkib, are designed for specific genetic mutations in non-small cell lung cancer and are currently under FDA review. The deal also encompasses an early-stage medicine and Nuvalent’s preclinical portfolio. GSK CEO Luke Miels emphasized the strategic value of the acquisition, stating it would provide “immediate new sales growth opportunities” and offer significant treatment options for patients with two forms of lung cancer. Analysts at Barclays acknowledged the deal’s potential to accelerate GSK’s entry into the lung cancer space but questioned whether the two late-stage assets would achieve “mega blockbuster” status. They noted the upside for zidesamtinib and neladalkib was “capped” and highlighted the importance of the acquisition in offsetting revenue losses from the HIV drug’s patent expiration, which is projected to impact GSK starting mid-2028. The company reiterated that its 2026 financial guidance remains unchanged, with the acquisition expected to contribute to revenue growth beginning in 2027.#london #lung_cancer #gsk #nuvalent #ros1_positive_non_small_cell_lung_cancer
